- Home
- MGNX vs MACI Comparison
MGNX vs MACI Comparison
Compare MGNX & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MACI
- Stock Information
- Founded
- MGNX 2000
- MACI 2024
- Country
- MGNX United States
- MACI United States
- Employees
- MGNX N/A
- MACI N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MACI
- Sector
- MGNX Health Care
- MACI
- Exchange
- MGNX Nasdaq
- MACI NYSE
- Market Cap
- MGNX 202.7M
- MACI 219.7M
- IPO Year
- MGNX 2013
- MACI 2024
- Fundamental
- Price
- MGNX $2.86
- MACI $10.16
- Analyst Decision
- MGNX Hold
- MACI
- Analyst Count
- MGNX 10
- MACI 0
- Target Price
- MGNX $7.17
- MACI N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- MACI 14.7K
- Earning Date
- MGNX 03-06-2025
- MACI 01-01-0001
- Dividend Yield
- MGNX N/A
- MACI N/A
- EPS Growth
- MGNX N/A
- MACI N/A
- EPS
- MGNX N/A
- MACI N/A
- Revenue
- MGNX $141,329,000.00
- MACI N/A
- Revenue This Year
- MGNX $174.73
- MACI N/A
- Revenue Next Year
- MGNX N/A
- MACI N/A
- P/E Ratio
- MGNX N/A
- MACI N/A
- Revenue Growth
- MGNX 16.68
- MACI N/A
- 52 Week Low
- MGNX $2.79
- MACI $9.95
- 52 Week High
- MGNX $21.88
- MACI $10.20
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- MACI N/A
- Support Level
- MGNX $2.93
- MACI N/A
- Resistance Level
- MGNX $3.16
- MACI N/A
- Average True Range (ATR)
- MGNX 0.18
- MACI 0.00
- MACD
- MGNX -0.02
- MACI 0.00
- Stochastic Oscillator
- MGNX 1.90
- MACI 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.